Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that discovered, developed and is commercializing innovative therapies based upon tetracycline chemistry. The company was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek's research and development efforts have resulted in the FDA approval of two novel therapeutic products, NUZYRA® (omadacycline) for adults and for pediatric patients ages six months and older, and the recently approved SIVEXTRO® (tedizolid phosphate) for adults and is developing others.
